Epoetin delta

Drug Profile

Epoetin delta

Alternative Names: Dynepo; GA-EPO; Gene-activated epoetin alfa; Gene-activated epoetin alpha; Gene-activated erythropoietin; HMR 4396; MDL 104396; Recombinant human erythropoietin δ

Latest Information Update: 01 Jul 2009

Price : $50

At a glance

  • Originator sanofi-aventis; Shire Pharmaceuticals Group
  • Developer sanofi-aventis; Shire; Shire plc
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Anaemia

Most Recent Events

  • 31 Dec 2008 Withdrawn for Anaemia in United Kingdom (SC)
  • 31 Dec 2008 Withdrawn for Anaemia in Italy (SC)
  • 31 Dec 2008 Withdrawn for Anaemia in Ireland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top